Zobrazeno 1 - 10
of 10
pro vyhledávání: '"I. A. Tishaeva"'
Autor:
O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, I. A. Li, D. V. Podolskaya, T. V. Shkurko, B. A. Nanaeva, T. L. Aleksandrov, T. A. Baranova, I. A. Tishaeva, M. Yu. Zvyaglova, A. I. Parfenov
Publikováno v:
Медицинский совет, Vol 0, Iss 15, Pp 20-29 (2021)
Introduction. Tofacitinib is the first member of a new class of targeted synthetic anti-inflammatory drugs for the treatment of ulcerative colitis (UC). The article presents a three-year Russian experience of tofacitinib use for the treatment of mode
Externí odkaz:
https://doaj.org/article/f0ccd53b02d34cefa5b317533f978e88
Autor:
I. L. Khalif, I. A. Tishaeva
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 27, Iss 4, Pp 22-27 (2018)
Aim of review. To present the literature data on efficacy of the diet with decreased content of fermentable oligo, di and monosaccharides and polyols (low FODMAP diet) for irritable bowel syndrome (IBS) treatment. Summary. The role of fermentable
Externí odkaz:
https://doaj.org/article/4a7b6fcc80294c11a10ac2c757aaeefa
Autor:
I. A. Tishaeva, O. V. Knyazev, T. A. Baranova, D. V. Podolskaya, T. L. Alexandrov, B. A. Nanaeva
Publikováno v:
Koloproktologia. 22:99-107
AIM: detection of steroid dependence and steroid resistance predictors in patients with ulcerative colitis (UC).PATIENTS AND METHODS: a retrospective study was conducted. The medical documentation of 1105 patients, who underwent inpatient treatment i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc38b09b6ba0aba251bc9c3aa7910fd6
https://doi.org/10.33878/2073-7556-2023-22-1-99-107
https://doi.org/10.33878/2073-7556-2023-22-1-99-107
Publikováno v:
Experimental and Clinical Gastroenterology. :268-275
Currently, there are limited national data on the dose-dependent effect and long-term results of glucocorticosteroid (GCS) therapy in severe attacks of ulcerative colitis (UC). Approximately 20% of UC patients have chronic active disease, which requi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f625c51db10d4762d0aedd6ab5ec0b2
https://doi.org/10.31146/1682-8658-ecg-205-9-268-275
https://doi.org/10.31146/1682-8658-ecg-205-9-268-275
Autor:
E. S. Peda, T. L. Alexandrov, T. A. Baranova, S. S. Belous, I. A. Tishaeva, B. A. Nanaeva, M. V. Shapina, O. V. Knyazev, R. R. Eligulashvili, V. A. Belinskaya, D. V. Podolskaya
Publikováno v:
Experimental and Clinical Gastroenterology. :35-41
Introduction. Inflammatory bowel diseases are a group of chronic, immune-mediated diseases of unknown etiology. Etiotropic therapy of IBD does not exist, all drugs used to treat IBD have a pathogenetic effect. In the treatment of IBD biologic therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eee8e0895b0bb8ffad44095b036e2d47
https://doi.org/10.31146/1682-8658-ecg-195-11-35-41
https://doi.org/10.31146/1682-8658-ecg-195-11-35-41
Autor:
Oleg Knyazev, T.V. Shkurko, T. A. Baranova, A I Parfenov, B. A. Nanaeva, A V Kagramanova, M.Yu. Zvyaglova, T. L. Aleksandrov, I. A. Tishaeva, D. V. Podolskaya, I Li, A A Lishchinskaya
Publikováno v:
Медицинский совет, Vol 0, Iss 15, Pp 20-29 (2021)
Introduction. Tofacitinib is the first member of a new class of targeted synthetic anti-inflammatory drugs for the treatment of ulcerative colitis (UC). The article presents a three-year Russian experience of tofacitinib use for the treatment of mode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4381f2e6c892130fc0c66b1c9d29cc
https://doi.org/10.21518/2079-701x-2021-15-20-29
https://doi.org/10.21518/2079-701x-2021-15-20-29
Autor:
M. V. Shapina, O. V. Knyazev, D. V. Podolskaya, T. A. Baranova, I. A. Tishaeva, T. L. Alexandrov, B. A. Nanaeva
Publikováno v:
Koloproktologia. 20:43-50
AIM: to evaluate the effectiveness of tofacitinib as a second line treatment.PATIENTS AND METHODS: the study included 12 patients, 4 (33.34%) males and 8 (66.66%) females. The median age was 41 ± 5 years. All patients admitted to the hospital with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48d0c1626fb367c059ccceca1a347aac
https://doi.org/10.33878/10.33878/2073-7556-2021-20-3-43-50
https://doi.org/10.33878/10.33878/2073-7556-2021-20-3-43-50
Autor:
M. V. Shapina, D. V. Podolskaya, E. S. Peda, I. A. Tishaeva, B. A. Nanaeva, T. L. Alexandrov, O. V. Knyazev, T. A. Baranova
Publikováno v:
Koloproktologia. 20:28-34
AIM: to evaluate the effect of cytomegalovirus (CMV) infection on the course of moderate and severe flare ups of ulcerative colitis (UC).PATIENTS AND METHODS: a prospective cohort single-center study was done in September 2018 — December 2020. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fd3ed2702531d81c71550b1f062b537
https://doi.org/10.33878/10.33878/2073-7556-2021-20-3-28-34
https://doi.org/10.33878/10.33878/2073-7556-2021-20-3-28-34
Publikováno v:
Тонкие химические технологии, Vol 12, Iss 4, Pp 98-105 (2017)
Due to the relevance of the problem of implementation of the Best Available Techniques (BAT) in the chemical industry of the Russian Federation it is necessary to develop a scientifically defensible transition process to BAT for chemical manufactures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43f2e50886fec6e0fc226e94bc641dda
https://doi.org/10.32362/2410-6593-2017-12-4-98-105
https://doi.org/10.32362/2410-6593-2017-12-4-98-105
Autor:
S. A. Panova, I. R. Tishaeva
Publikováno v:
Тонкие химические технологии, Vol 9, Iss 5, Pp 83-85 (2014)
A system model for the identification of the best available technology (BAT) was proposed on the basis of the system approach and the mathematical apparatus of set theory. The model allows to set up a problem of BAT identification for various chemica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::38d341be61184d0ac495f2172141d071
https://www.finechem-mirea.ru/jour/article/view/444
https://www.finechem-mirea.ru/jour/article/view/444